6A3A.F Autolus Therapeutics plc

Healthcare Biotechnology Frankfurt Exchange
1.12 EUR
Close of Nov 12, 2026
1.04 2.16
Market cap
EUR 298M
P/E
-
P/B
4.39x
ROE
-295.9%
Dividend yield
-
Fundamental score
-

Ratios use the latest price and the current fiscal year annualized from 2 quarters up to Jun 2026.

Is 6A3A.F undervalued?

Graham number

The Graham number of Autolus Therapeutics plc cannot be estimated reliably (it needs positive earnings and book value).

Graham number = √(22.5 × EPS × book value per share): the most a defensive investor should pay according to Benjamin Graham. An estimate, not a recommendation to buy or sell. How is it calculated?

Autolus Therapeutics plc fundamental analysis

No fundamental analysis for Autolus Therapeutics plc yet.

Autolus Therapeutics plc stock price

Prices on the chart can differ slightly from the closing prices StockSummer uses for its ratios.

About Autolus Therapeutics plc

Autolus Therapeutics plc, a clinical-stage biopharmaceutical company, develops T cell therapies for the treatment of cancer and autoimmune diseases in the United Kingdom and internationally. The company offers AUCATZYL, a gene therapy product consisting of autologous T cells that are transduced with a lentiviral vector to express a novel anti-CD19 chimeric antigen receptor. It also develops obe-cel, which is in phase 1 to treat systemic lupus erythematosus, progressive multi…

Full company profile